Gut Microbiome in DLBCL Treated With Glofitamab

Starting soon

Conditions studied: DLBCL, Glofitamab, Gut Biome

In brief

The gut microbiome (GM) has recently emerged as one of the key modifiable factors of response and prognosis to immunotherapy in cancer patients. Currently, it is unknown if GM also modulates anti-tumor responses to T cell engagers (TCE) including glofitamab in DLBCL patients.

Key facts

Study ID

NCT07498920

Run by

Peking Union Medical College Hospital

People needed

30

Starts

2026-04-01

Expected to finish

2029-12-31

Last updated by the study team

2026-03-27

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically/cytologically confirmed diagnosis of DLBCL
• Is being planned to received Glofitamab
• Be able to provide written informed consent

You may not qualify if…

• Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results.
• Concurrent second malignancy.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.